Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2439389 | 1.00 | SLC6A4 (0.38) | SLC6A4DRD2HTR2AHSD11B1ADRA1D | |
| SCHEMBL13448813 | 1.00 | SLC6A4 (0.38) | SLC6A4DRD2HTR2AHSD11B1ADRA1D | |
| SCHEMBL12329382 | 0.88 | DRD2 (0.40) | SLC6A4DRD2HTR2AHSD11B1ADRA1D | |
| SCHEMBL12299545 | 0.86 | ELANE (0.35) | SLC6A4DRD2HTR2AHSD11B1ADRA1D | |
| SCHEMBL2440387 | 0.86 | ELANE (0.35) | SLC6A4DRD2HTR2AHSD11B1ADRA1D | |
| SCHEMBL13448846 | 0.85 | DRD2 (0.39) | SLC6A4DRD2HTR2AHSD11B1ADRA1D | |
| SCHEMBL12299552 | 0.85 | DPP8 (0.41) | SLC6A4DRD2HTR2AHSD11B1ADRA1D | |
| SCHEMBL2439712 | 0.85 | DPP8 (0.41) | SLC6A4DRD2HTR2AHSD11B1ADRA1D | |
| SCHEMBL1923727 | 0.84 | TDO2 (0.39) | SLC6A4DRD2HTR2AADRA1DIDO1 | |
| SCHEMBL12299635 | 0.84 | TDO2 (0.39) | SLC6A4DRD2HTR2AADRA1DIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
| WO-2010033531-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | SLC6A4 4458/4885DRD2 4857/4885HTR2A 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.